LianBio appoints Wei Wei Chen as independent director and Audit Committee member

LianBio

Wei Wei Chen appointed to LianBio Board as Class II director effective April 6, 2022; term ends at 2023 annual shareholder meeting.
Chen also appointed to the Audit Committee of the Board.
Chen brings 17+ years CFO experience, most recently at Starbucks China; previously CFO at Yum! Brands China and Sanofi Asia.
No arrangement or understanding with any other person led to selection; no related-party transactions requiring disclosure.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Wei Wei Chen

independent director

LIANY · LianBio

Effective: 2022-04-06
Filed: April 8, 2022, 7:59 PM ET

On April 6, 2022, the Board of Directors (the “Board”) of LianBio (the “Company”) appointed Wei Wei Chen as an independent director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Wei Wei Chen was appointed as independent director at LianBio.

Action: appointed
Role: independent director

Exact text from the filing

On April 6, 2022, the Board of Directors (the “Board”) of LianBio (the “Company”) appointed Wei Wei Chen as an independent director, effective immediately.

View on SEC.gov

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-22-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.